First biologic for severe eczema okayed for teens
Although it is confined to the private market, there is a renewed bid for PBS listing
The first targeted biologic to treat moderate-to-severe atopic dermatitis can now be prescribed to patients as young as 12 via private script.
Dupilumab (Dupixent) is an alternative to topical corticosteroids and topical calcineurin inhibitors that is TGA registered for use in adults, and now adolescents, with severe forms of atopic dermatitis.
The monoclonal antibody selectively inhibits the signaling of type two cytokines, interleukin-4 and interleukin-13.
But with a price tag of $1615.38 for two 300mg injections — which is the monthly dose for adults after an initial 600mg loading dose — the therapy is costly for patients.
